Core Technology Introduction

Core technology introduction:

  1. Discovered X.msc and successfully developed incubation technologies, including culture medium and environment, have been patented. This is the core technology for the reproduction and activation of purified X.msc.
  2. Successful development of multi-generation cultivation technology, maintaining constant activity, can solve the problem of the source of quantitative production, as well as improve safety and reduce the load of risk management costs. This is an important industrial technology breakthrough, greatly reducing production costs and improving safety and productivity.
  3. Complete theoretical basic research, master the characteristics of mesenchymal stem cells, and can be more accurately applied and derived application development.

    The outstanding research results unique to X.msc are presented below (six key points):
    a. X.msc has the characteristics of being safe to use throughout the body without promoting cancer. Experiments have shown that most autologous or allogeneic mesenchymal stem cells have a cancer-promoting effect. There are certain risks in using it throughout the body, highlighting the application value of X.msc. The reason why it does not promote cancer and the related receptors have been confirmed, and related papers will be published in the near future.
    b. X.msc has very powerful immunomodulatory effects. The special dual effect has enhanced effects in many wound treatments. It is also the most promising stem cell for treating many autoimmune diseases. cancer and the related receptors have been confirmed, and related papers will be published in the near future.
    c. It has been found that X.msc secretes components that can temporarily inhibit apoptosis and play an important role in wound treatment.
    d. It was found that it has activated autologous stem cells, activated cell functions at the wound, and regenerated and repaired to achieve rapid and complete tissue reconstruction.
    e. Discover the unique characteristics of Xmsc. Each Xmsc has both estrogen receptor (ER) and progesterone (PR), so it has great potential for application development.
    f. X.msc’s “exosome” has a large secretion and strong activity! The research found that compared with other stem cells, there is a very large difference. The technology of “functionalized exosomes” has been developed successfully. A variety of X.exosome products have been launched, which can be developed for new drugs and applied across fields longevity health, medical beauty and anti-aging….4) 
  4. For the immune system diseases and tissue regeneration and repair applications, nearly fifteen years of research, significant efficacy and complete experimental data, many project results have reached the conditions for immediate human clinical trial application.
  5. The planned clinical trials for the first batch of applications (IND) are based on the project of affiliated scientific research company BioSeed to invest in the development of new drugs. It is estimated that the clinical license applications for its eight projects will be completed in 2021.

    a. Acute lung failure (ARDS) treatment → Chronic pulmonary fibrosis (COPD) improvement
    b. Treatment of multiple sclerosis (MS) → Autoimmune diseases of cerebral ganglia, improvement of autoimmune disorders
    c. Diabetic wound healing (DMFU)
    d. Radiation wound healing (RI), cancer surgery wound recovery
    e. Hemorrhagic stroke (ICH) treatment
    f. Asthma (AS) → Treatment of autoimmune diseases
    g. Cell sheet (CS) → Skin and internal surgery combined with medical treatment
    h. Special medication → Nuclear skin wound treatment (medicine for war preparations), various skin wound treatments

    The clinical trial applications are mainly based on the US FDA, supplemented by Taiwan.

     Experimental hospitals and doctors are initially in Taiwan. Career development and capital operations are planned in five regions. The schedule is to complete the IND preparation work in the first half of 2020, scheduling cells for clinical trials has begun ⋯

  6. The experimental results of cytotherapy are remarkable. The items to be developed are: burns and scalds, acute nephritis, uterine scratches, transplanted organ rejection, lupus erythematosus and psoriasis, and eye diseases (dry eye, caliber eye, macular degeneration, optic nerve atrophy, red color inflammation, allergies, infection inflammation, comprehensive aging ⋯), alcoholic cirrhosis, cancer wound healing, adjuvant cancer treatment. 
Scroll to Top